Hawaii Lawmakers Advance Bill to Establish Psychedelics Task Force for Psilocybin and MDMA Policy Study

Hawaii legislators are making significant strides toward evaluating the therapeutic potential of psychedelics, as a House committee unanimously approved a bill to create a dedicated task force for studying psilocybin and MDMA therapies. The House Finance Committee voted 15-0 in favor of the measure, which had already passed the Senate with a unanimous 24-0 vote. The legislation now moves to the House floor and may return to the Senate for review of recent amendments before final approval

The proposed Mental Health Emerging Therapies Task Force would spend two years reviewing scientific research, supporting additional clinical studies, and developing policy recommendations for the safe and culturally-informed implementation of psychedelic therapies in Hawaii. According to the bill, "The legislature finds that addressing the mental health crisis affecting the residents of the State, particularly among veterans, first responders, and trauma survivors, is urgent." The bill notes that suicide remains a leading cause of preventable death, and underscores the need to explore all scientifically supported treatment options

Federal developments have played a key role in shaping the proposed legislation. The U.S. Food and Drug Administration has already designated psilocybin and MDMA as 'breakthrough therapies' for certain mental health conditions, which could lead to federal rescheduling of these substances. In response, the Hawaii measure emphasizes the importance of proactively preparing state health, clinical, and research systems to safely and equitably implement these therapies. The Department of Health expressed support for the bill, stating, "it is prudent for Hawaii to evaluate research readiness, regulatory implications, workforce development, and culturally informed implementation pathways" in anticipation of possible federal changes

The composition and leadership of the task force have evolved through legislative amendments. While the Department of Health was initially set to oversee the panel, the House Health Committee amended the bill to place responsibility with the John A. Burns School of Medicine at the University of Hawaii, with its appointee serving as chair. Additional amendments clarified that the Narcotics Enforcement Division would be responsible for state scheduling changes following federal reclassification, shortening the deadline for such actions from 90 to 30 days. The State Health Planning & Development Agency cautioned that psychedelics remain illegal under federal law and urged a careful approach

This initiative builds on Hawaii’s previous efforts, following a similar task force convened in 2023 to explore therapeutic access to FDA-approved breakthrough drugs like psilocybin. Meanwhile, other drug policy reforms have faced obstacles in the state legislature, with bills to legalize low-dose marijuana and expand hemp-derived cannabinoid sales failing to advance this session. Nonetheless, lawmakers have shown support for improving medical cannabis access and urging federal reforms on marijuana legalization and banking

From the OG Lab newsroom perspective, Hawaii’s move to establish a psychedelics policy task force reflects growing recognition of the mental health crisis and the potential of novel therapies. As federal policy on psychedelics evolves, Hawaii’s proactive approach could serve as a model for other states seeking to balance innovation with regulatory caution. The cannabis and psychedelics industries should closely monitor Hawaii’s next legislative steps, as the outcomes could shape future frameworks for therapeutic access nationwide